Silexion Therapeutics (SLXN) Non-Current Assets (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Non-Current Assets of $537000.0 for Q1 2026, down 8.36% year-over-year from $586000.0 in Q1 2025, and down 7.09% quarter-over-quarter from $578000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Non-Current Assets (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $537000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.36% year-over-year to $537000.0; the TTM figure through Mar 2026 stood at $537000.0 (down 8.36% YoY), while the FY2025 annual figure was $578000.0, down 5.71% from the prior year.
- Non-Current Assets for Q1 2026 stood at $537000.0, down from $578000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $613000.0 in Q4 2024, with the low at $40000.0 in Q3 2024.
- The 4-year median for Non-Current Assets is $559000.0 (2025), against an average of $440000.0.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 1297.5% in 2025, then dropped 8.36% in 2026.
- Silexion Therapeutics' Non-Current Assets stood at $277000.0 in 2023, then surged by 121.3% to $613000.0 in 2024, then fell by 5.71% to $578000.0 in 2025, then declined by 7.09% to $537000.0 in 2026.
- Business Quant data shows SLXN's Non-Current Assets at $537000.0 in Q1 2026, $578000.0 in Q4 2025, and $559000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | Silexion Therapeutics | 261,881.50 | -1.97 Mn | - | 505,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 505,000.00 |
| Mar 31, 2026 | 537,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 560,000.00 |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 613,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 210,000.00 |
| Dec 31, 2023 | 277,000.00 |